Extract to table
Pull the structured facts out of a document: parties, dates, amounts, obligations.
Extract to table / letter-transmitting-near-final-draft.docx
letter-transmitting-near-final-draft.docx
Parties
HARKNESS LLP
Callahan LLP
Penterra Pharmaceuticals Corp
Key Revisions Inc
Dates
June 16, 2023
June 9, 2023
June 12, 2023
May 19, 2023
May 5, 2023
June 21, 2023
June 23, 2023
June 28, 2023
August 14, 2023
Amounts
$500,000
$15,000,000
$5,000,000
$20,000,000
$25,000,000
$75,000,000
$10,000,000
$50,000,000
$52,000
$13,000
Obligations
Importantly, and as specifically agreed at the June 9 session, the MCTA provides that indemnification for claims arising from product defects shall be uncapped, reflecting the parties' mutual understanding that defect-based claims properly rest with the sponsor
Certificates of insurance shall be exchanged within 15 business days of execution of the MCTA and annually thereafter for the duration of the study
Each party shall provide at least 30 days' prior written notice of any material change in, cancellation of, or non-renewal of any required insurance coverage
Where an investigator deviates from the Protocol as necessary to protect the immediate safety or well-being of a study subject, no liability shall be allocated to the investigator or site, and such deviations shall not constitute a basis for any carve-out from Penterra's indemnification obligations
Where a deviation from the Protocol has been authorized by Penterra in writing prior to its occurrence, such deviation shall be treated as an amendment to the Protocol for purposes of indemnification, and liability shall not be allocated to the investigator or site
Where a site or investigator deviates from the Protocol without prior written authorization from Penterra and outside the scope of immediate subject safety, such deviation shall be allocated to the site and investigator under the reciprocal indemnification provisions of Exhibit D